VJHemOnc is committed to improving our service to you

ASH 2019 | Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma

VJHemOnc is committed to improving our service to you

Anas Younes

Dual inhibition of BCL2 and MCL1, using the small molecule inhibitors venetoclax and S63845, can lead to sustained and durable remissions in mice harboring human diffuse large B-cell lymphoma (DLBCL) tumors. However, combination treatment was also associated with significant weight loss and hematological toxicity. Anas Younes, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines a pre-clinical study where MCL1 or BCL2 inhibitors were encapsulated into lymphoma-targeting nanoparticles to reduce toxicity. When combination therapy was administered with one drug encapsulated as a nanoparticle, no significant weight loss or hematological toxicity were observed, demonstrating that this nanoparticle delivery system maintains therapeutic value while sparing normal cells from treatment toxicity. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter